Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.
about
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Antigen Loss Variants: Catching Hold of Escaping Foes.Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.Blinatumomab bridges the gap between leukemia and immunity.Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Mono- and dual-targeting tripl ...... chronic lymphocytic leukemia.
@en
type
label
Mono- and dual-targeting tripl ...... chronic lymphocytic leukemia.
@en
prefLabel
Mono- and dual-targeting tripl ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P50
P1433
P1476
Mono- and dual-targeting tripl ...... chronic lymphocytic leukemia.
@en
P2093
Hinrich P Hansen
Katrin S Reiners
Olga Shatnyeva
Samir Tawadros
Stephan Kloess
Ulrike Köhl
P2860
P304
P356
10.1080/2162402X.2016.1211220
P577
2016-07-15T00:00:00Z